sirturo 100mg tablets
johnson & johnson sdn. bhd. - bedaquiline fumarate -
thyrosafe- potassium iodide tablet
recipharm ab (publ) - potassium iodide (unii: 1c4qk22f9j) (iodide ion - unii:09g4i6v86q) - potassium iodide 65 mg - thyroid blocking use helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. use along with other emergency measures recommended by public officials.
montelukast tablet, film coated montelukast tablet, chewable
recipharm pharmaservices private limited - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 10 mg - montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. hypersensitivity to any component of this product. pregnancy category b: there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, montelukast sodium should be used during pregnancy only if clearly needed. teratogenic effect: no teratogenicity was observed in rats and rabbits at doses approximately 100 and 110 times, respectively, the maximum recommended daily oral dose in adults based on aucs
driptane
recipharm fontaine - oxybutynin (oxybutynin hydrochloride) - tablets - 5mg
tricor tablets film-coated
recipharm fontaine - fenofibrate - tablets film-coated - 145mg
driptane tablets
recipharm fontaine - oxybutynin (oxybutynin hydrochloride) - tablets - 5mg
driptane tablets
recipharm fontaine - oxybutynin (oxybutynin hydrochloride) - tablets - 5mg
tricor tablets film-coated
recipharm fontaine - fenofibrate - tablets film-coated - 145mg
flutiform 505
rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.05 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 50mcg/5mcg inhaler is indicated in adults, adolescents and children aged 5 years and above.
flutiform 1255
rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 125mcg/5mcg inhaler is indicated in adults and adolescents aged 12 years and above.